Marshall Wace LLP Has $59.34 Million Position in Repligen Co. (NASDAQ:RGEN)

Marshall Wace LLP raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 73.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 412,235 shares of the biotechnology company's stock after buying an additional 175,013 shares during the quarter. Marshall Wace LLP owned 0.74% of Repligen worth $59,337,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Stifel Financial Corp grew its stake in shares of Repligen by 5.4% in the third quarter. Stifel Financial Corp now owns 4,404 shares of the biotechnology company's stock valued at $655,000 after acquiring an additional 226 shares in the last quarter. MML Investors Services LLC grew its position in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after purchasing an additional 89 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Repligen during the third quarter worth approximately $233,000. Tidal Investments LLC raised its position in shares of Repligen by 142.8% in the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company's stock valued at $1,659,000 after buying an additional 6,558 shares in the last quarter. Finally, Peapack Gladstone Financial Corp bought a new stake in shares of Repligen in the third quarter valued at approximately $296,000. Institutional investors own 97.64% of the company's stock.

Insiders Place Their Bets

In related news, Director Margaret Pax bought 250 shares of the business's stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Stock Down 1.6 %

Shares of RGEN opened at $130.00 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52 week low of $102.97 and a 52 week high of $182.52. The stock has a market capitalization of $7.30 billion, a price-to-earnings ratio of -254.90, a PEG ratio of 4.54 and a beta of 1.27. The stock has a fifty day moving average of $140.76 and a 200-day moving average of $145.82.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Royal Bank of Canada boosted their price target on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. Finally, Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $176.82.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.